Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

60.16
+0.16000.27%
Post-market: 60.160.00000.00%19:33 EDT
Volume:637.20K
Turnover:38.44M
Market Cap:5.81B
PE:-12.78
High:61.75
Open:60.56
Low:59.68
Close:60.00
52wk High:72.66
52wk Low:35.60
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.87
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:4.68
PE(LYR):-13.78

Loading ...

Is Xenon Pharmaceuticals (XENE) Attractive After Recent Pullback And Strong One Year Rally

Simply Wall St.
·
Apr 25

What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders

Simply Wall St.
·
Apr 22

Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB)

TIPRANKS
·
Apr 20

Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study

TIPRANKS
·
Apr 20

Xenon says Phase 3 X-TOLE2 trial shows azetukalner cuts monthly seizures 53%

Reuters
·
Apr 20

Assessing Xenon Pharmaceuticals (XENE) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
Apr 18

Xenon Pharmaceuticals to present at Bloom Burton healthcare investor conference

Reuters
·
Apr 15

Xenon expands 2025 inducement equity plan share reserve to 1,175,000 shares

Reuters
·
Apr 14

Xenon highlights Phase 3 X-TOLE2 azetukalner data in focal onset seizures at AAN 2026

Reuters
·
Apr 07

How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors

Simply Wall St.
·
Mar 30

Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 16

Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $63 From $64

THOMSON REUTERS
·
Mar 16

Wedbush Trims Price Target on Xenon Pharmaceuticals to $63 From $64, Keeps Outperform Rating

MT Newswires Live
·
Mar 16

H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)

TIPRANKS
·
Mar 16

Xenon Pharmaceuticals Closes $747.5 Million Public Offering

MT Newswires Live
·
Mar 13

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Mar 13

Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares

Reuters
·
Mar 12

BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Nike, Unifirst

Reuters
·
Mar 11

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

TIPRANKS
·
Mar 11

Xenon Pharmaceuticals prices upsized USD 650 million public offering at USD 57 per share

Reuters
·
Mar 11